MetaCap

Mentari Therapeutics (MTRI) vs Pharming Group N.V. (PHAR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Mentari Therapeutics is the larger company by market cap ($856.9 million vs $816.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MTRI+0.68%PHAR-2.12%
+39%+7%-26%
Aug 17, 20261 yearNov 20, 2026
MTRI+0.68%PHAR-2.62%
+30%+3%-23%
Aug 17, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MTRI versus PHAR key metrics
MetricMTRIPHAR
Share price$14.70$11.54
Market cap$856.94M$816.78M
1-day change-3.57%-5.10%
YTD return—-34.69%
1-year return—-29.03%
5-year return—+39.04%
P/E ratio (TTM)—36.06
Forward P/E—64.11
EPS (TTM)—$0.32
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$376.13M
Revenue growth (YoY)—+26.56%
Net income (latest FY)—$2.85M
Gross margin—87.90%
Operating margin—6.87%
Net margin—0.76%
52-week high$23.30$21.34
52-week low$5.75$9.11
Distance from 52-week high-36.91%-45.92%
Analyst consensusstrong_buystrong_buy
Avg. price target upside—+209.36%
Average volume19.42K21.33K
Shares outstanding58.30M70.78M
Employees—407
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Mentari Therapeutics

MTRI stock →

Mentari Therapeutics, Inc., a biotechnology company, develops and provides therapies for migraine prevention. The company's products include MT-001, an anti-PACAP monoclonal antibody designed for convenient subcutaneous dosing; MT-002, an anti-CGRP; and anti-PACAP bispecific antibody designed to inhibit these complementary pathways.

Health Care · Biotechnology: Pharmaceutical Preparations

About Pharming Group N.V.

PHAR stock →

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kd inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 407 employees

MTRI vs PHAR FAQ

Which is bigger, Mentari Therapeutics or Pharming Group N.V.?

Mentari Therapeutics (MTRI) is larger, with a market capitalization of $856.94M compared with $816.78M for Pharming Group N.V. (PHAR).

Are Mentari Therapeutics and Pharming Group N.V. in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons